{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:35Z","timestamp":1789624955630,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG078759"],"award-info":[{"award-number":["R01AG078759"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00198-025-07544-8","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:36:30Z","timestamp":1749648990000},"page":"1277-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The rise and fall of raloxifene use for osteoporosis, 1999\u20132022"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1222-8524","authenticated-orcid":false,"given":"Freddy F.","family":"Shogry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-0071","authenticated-orcid":false,"given":"Kaleen N.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-2563","authenticated-orcid":false,"given":"Sandra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea M.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3288-2863","authenticated-orcid":false,"given":"Sulbh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"4","key":"7544_CR1","first-page":"1131","volume":"60","author":"JA Scott","year":"1999","unstructured":"Scott JA, Da Camara CC, Early JE (1999) Raloxifene: a selective estrogen receptor modulator. Am Fam Physician 60(4):1131\u20131139","journal-title":"Am Fam Physician"},{"key":"7544_CR2","unstructured":"Drug and Health Product Portal - \u2018EVISTA \u00ae (raloxifene hydrochloride) 60 mg Tablets Selective Estrogen Receptor Modulator. https:\/\/dhpp.hpfb-dgpsa.ca\/dhpp\/resource\/62480.  Accessed 24 Jan 2025"},{"issue":"7","key":"7544_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-Year randomized clinical trial. JAMA 282(7):637\u2013645. https:\/\/doi.org\/10.1001\/jama.282.7.637","journal-title":"JAMA"},{"key":"7544_CR4","unstructured":"Evista | Notice of Compliance Information. https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=3141. Accessed 24 Jan 2025"},{"key":"7544_CR5","unstructured":"Evista@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020815.  Accessed 24 Jan 2025"},{"key":"7544_CR6","unstructured":"Evista | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evista.  Accessed  24 Jan 2025"},{"key":"7544_CR7","unstructured":"FDA Approves Lilly\u2019s Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women | Eli Lilly and Company. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-osteoporosis-drug-evistar-raloxifene-hcl.  Accessed 24 Jan 2025"},{"issue":"2","key":"7544_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125\u2013137","journal-title":"N Engl J Med"},{"key":"7544_CR9","unstructured":"Archived - Evista (raloxifene hydrochloride) Advisories, Warnings and Recalls for Health Professionals - Recalls, advisories and safety alerts \u2013 Canada.ca. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/archived-evista-raloxifene-hydrochloride-advisories-warnings-and-recalls-health.  Accessed  24 Jan 2025"},{"issue":"39","key":"7544_CR10","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Can Med Assoc J: CMAJ 195(39):E1333\u2013E1348. https:\/\/doi.org\/10.1503\/cmaj.221647","journal-title":"Can Med Assoc J: CMAJ"},{"issue":"10131","key":"7544_CR11","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(18)30181-8","volume":"391","author":"D Martin","year":"2018","unstructured":"Martin D, Miller AP, Quesnel-Vall\u00e9e A et al (2018) Canada\u2019s universal health-care system: achieving its potential. The Lancet 391(10131):1718\u20131735. https:\/\/doi.org\/10.1016\/S0140-6736(18)30181-8","journal-title":"The Lancet"},{"issue":"3","key":"7544_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4212\/cjhp.v68i3.1457","volume":"68","author":"SM Cadarette","year":"2015","unstructured":"Cadarette SM, Wong L (2015) An introduction to health care administrative data. Can J Hosp Pharm 68(3):232\u2013237","journal-title":"Can J Hosp Pharm"},{"key":"7544_CR13","unstructured":"Get coverage for prescription drugs | ontario.ca. http:\/\/www.ontario.ca\/page\/get-coverage-prescription-drugs.  Accessed  24 Jan 2025"},{"key":"7544_CR14","unstructured":"Applying to the Exceptional Access Program | ontario.ca. http:\/\/www.ontario.ca\/page\/applying-exceptional-access-program.  Accessed  24 Jan 2025"},{"key":"7544_CR15","unstructured":"Ontario Drug Benefit Formulary\/Comparative Drug Index Edition 43. https:\/\/www.ontario.ca\/files\/2024-04\/moh-formulary-edition-43-2024-04-02.pdf. Accessed 24 Jan 2025"},{"key":"7544_CR16","unstructured":"Formulary Search: Ontario Drug Benefit Formulary\/Comparative Drug Index. Ontario Ministry of Health and Long-Term Care; 2023. https:\/\/www.formulary.health.gov.on.ca\/formulary\/.  Accessed 24 Jan  2025"},{"issue":"5","key":"7544_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00198-010-1329-8","volume":"22","author":"SM Cadarette","year":"2011","unstructured":"Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM (2011) Osteoporosis quality indicators using healthcare utilization data. Osteoporos Int 22(5):1335\u20131342. https:\/\/doi.org\/10.1007\/s00198-010-1329-8","journal-title":"Osteoporos Int"},{"issue":"2","key":"7544_CR18","first-page":"67","volume":"10","author":"AR Levy","year":"2003","unstructured":"Levy AR, O\u2019Brien BJ, Sellors C, Grootendorst P, Willison D (2003) Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 10(2):67\u201371","journal-title":"Can J Clin Pharmacol"},{"key":"7544_CR19","unstructured":"Personal Health Information Protection Act, 2004, S.O. 2004, c. 3, Sched. A | ontario.ca. https:\/\/www.ontario.ca\/laws\/statute\/04p03.  Accessed 24 Jan 2025"},{"key":"7544_CR20","unstructured":"Kralj B. Measuring Rurality - RIO2008_BASIC: Methodology and Results. https:\/\/www.hqontario.ca\/Portals\/0\/documents\/pr\/hqo-geographic-location-methods-review-report.pdf. Accessed 24 Jan 2025"},{"issue":"6","key":"7544_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1155\/2009\/963098","volume":"16","author":"AS Gershon","year":"2009","unstructured":"Gershon AS, Wang C, Guan J et al (2009) Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 16(6):183\u2013188. https:\/\/doi.org\/10.1155\/2009\/963098","journal-title":"Can Respir J"},{"issue":"5","key":"7544_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/15412550903140865","volume":"6","author":"AS Gershon","year":"2009","unstructured":"Gershon AS, Wang C, Guan J et al (2009) Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD 6(5):388\u2013394. https:\/\/doi.org\/10.1080\/15412550903140865","journal-title":"COPD"},{"issue":"3","key":"7544_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.24095\/hpcdp.33.3.06","volume":"33","author":"SE Schultz","year":"2013","unstructured":"Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33(3):160\u2013166","journal-title":"Chronic Dis Inj Can"},{"issue":"1","key":"7544_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","volume":"18","author":"LL Lipscombe","year":"2018","unstructured":"Lipscombe LL, Hwee J, Webster L et al (2018) Identifying diabetes cases from administrative data: a population-based validation study. BMC Health Serv Res 18(1):316. https:\/\/doi.org\/10.1186\/s12913-018-3148-0","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"7544_CR25","first-page":"e18","volume":"1","author":"K Tu","year":"2007","unstructured":"Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA (2007) Accuracy of administrative databases in identifying patients with hypertension. Open Med 1(1):e18\u2013e26","journal-title":"Open Med"},{"issue":"1","key":"7544_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JAD-160105","volume":"54","author":"RL Jaakkimainen","year":"2016","unstructured":"Jaakkimainen RL, Bronskill SE, Tierney MC et al (2016) Identification of physician-diagnosed Alzheimer\u2019s disease and related dementias in population-based administrative data: a validation study using family physicians\u2019 electronic medical records. Journal of Alzheimer\u2019s Disease 54(1):337\u2013349. https:\/\/doi.org\/10.3233\/JAD-160105","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"7544_CR27","doi-asserted-by":"publisher","first-page":"101730","DOI":"10.1016\/j.bonr.2023.101730","volume":"20","author":"KN Hayes","year":"2023","unstructured":"Hayes KN, Cadarette SM, Burden AM (2023) Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications. Bone Rep 20:101730. https:\/\/doi.org\/10.1016\/j.bonr.2023.101730","journal-title":"Bone Rep"},{"issue":"12","key":"7544_CR28","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","volume":"32","author":"AJ Singer","year":"2021","unstructured":"Singer AJ, Liu J, Yan H et al (2021) Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int 32(12):2473\u20132484. https:\/\/doi.org\/10.1007\/s00198-021-05951-1","journal-title":"Osteoporos Int"},{"issue":"5","key":"7544_CR29","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4158\/EP.12.5.522","volume":"12","author":"MP Ettinger","year":"2006","unstructured":"Ettinger MP, Gallagher R, MacCosbe PE (2006) Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12(5):522\u2013528. https:\/\/doi.org\/10.4158\/EP.12.5.522","journal-title":"Endocr Pract"},{"issue":"1","key":"7544_CR30","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate once-weekly study group. Aging (Milano) 12(1):1\u201312","journal-title":"Aging (Milano)"},{"issue":"17","key":"7544_CR31","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864\u20131873. https:\/\/doi.org\/10.1503\/cmaj.100771","journal-title":"CMAJ"},{"issue":"9","key":"7544_CR32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00198-019-05051-1","volume":"30","author":"JK Ban","year":"2019","unstructured":"Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM (2019) Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int 30(9):1865\u20131872. https:\/\/doi.org\/10.1007\/s00198-019-05051-1","journal-title":"Osteoporos Int"},{"issue":"5","key":"7544_CR33","doi-asserted-by":"publisher","first-page":"ziae027","DOI":"10.1093\/jbmrpl\/ziae027","volume":"8","author":"AM Rzepka","year":"2024","unstructured":"Rzepka AM, Cheung AM, Kim S, Gomes T, Cadarette SM (2024) On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal. JBMR Plus 8(5):ziae027. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae027","journal-title":"JBMR Plus"},{"issue":"6","key":"7544_CR34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00198-025-07484-3","volume":"36","author":"KN Hayes","year":"2025","unstructured":"Hayes KN, Zullo AR, Berry SD, Oganisian A, Aggarwal S, Adegboye M, Cadarette SM (2025) Osteoporosis medication use over time in the United States and Canada. Osteoporos Int 36(6):1089\u20131094. https:\/\/doi.org\/10.1007\/s00198-025-07484-3","journal-title":"Osteoporos Int"},{"key":"7544_CR35","unstructured":"Drug and Health Product Portal - PROLIA\u00ae (denosumab injection) 60 mg\/ mL solution 2010. https:\/\/dhpp.hpfb-dgpsa.ca\/dhpp\/resource\/82897. Accessed 24 Jan 2025"},{"issue":"3","key":"7544_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 288(3):321\u2013333. https:\/\/doi.org\/10.1001\/jama.288.3.321","journal-title":"JAMA"},{"issue":"14","key":"7544_CR37","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA 291(14):1701\u20131712. https:\/\/doi.org\/10.1001\/jama.291.14.1701","journal-title":"JAMA"},{"issue":"9","key":"7544_CR38","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s11606-007-0296-z","volume":"22","author":"TM Bush","year":"2007","unstructured":"Bush TM, Bonomi AE, Nekhlyudov L et al (2007) How the Women\u2019s Health Initiative (WHI) influenced physicians\u2019 practice and attitudes. J Gen Intern Med 22(9):1311\u20131316. https:\/\/doi.org\/10.1007\/s11606-007-0296-z","journal-title":"J Gen Intern Med"},{"issue":"3","key":"7544_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/j.ajkd.2021.06.031","volume":"79","author":"C Ginsberg","year":"2022","unstructured":"Ginsberg C, Ix JH (2022) Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis 79(3):427\u2013436. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.031","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"7544_CR40","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s00198-019-05061-z","volume":"30","author":"KN Hayes","year":"2019","unstructured":"Hayes KN, Ban JK, Athanasiadis G, Burden AM, Cadarette SM (2019) Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes. Osteoporos Int 30(11):2311\u20132319. https:\/\/doi.org\/10.1007\/s00198-019-05061-z","journal-title":"Osteoporos Int"},{"issue":"2","key":"7544_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/ph15020151","volume":"15","author":"Y Morofuji","year":"2022","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K et al (2022) Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel) 15(2):151. https:\/\/doi.org\/10.3390\/ph15020151","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"7544_CR42","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-020-05794-2","volume":"32","author":"KN Hayes","year":"2021","unstructured":"Hayes KN, He N, Brown KA et al (2021) Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use. Osteoporos Int 32(7):1413\u20131420. https:\/\/doi.org\/10.1007\/s00198-020-05794-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"7544_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jocd.2011.09.001","volume":"15","author":"P Narongroeknawin","year":"2012","unstructured":"Narongroeknawin P, Patkar NM, Shakoory B et al (2012) Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom 15(1):92\u2013102. https:\/\/doi.org\/10.1016\/j.jocd.2011.09.001","journal-title":"J Clin Densitom"},{"key":"7544_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/CLEP.S325080","volume":"13","author":"LA Stevens","year":"2021","unstructured":"Stevens LA, Spangler L, Yochum L, Ding Y, Wang FT (2021) Assessment of a claims-based ICD-9 and ICD-10 medication-related osteonecrosis of the jaw algorithm in the United States. CLEP 13:1019\u20131026. https:\/\/doi.org\/10.2147\/CLEP.S325080","journal-title":"CLEP"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07544-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T20:27:20Z","timestamp":1751315240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07544-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7544"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07544-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KNH has received investigator-initiated grant funding paid directly to Brown University from Sanofi, Genentech, and GlaxoSmithKline for research on influenza vaccination, influenza outbreak control, and shingles vaccination in nursing homes. Other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}